We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Biomarkers Provide Diagnostic Tool for AD

By LabMedica International staff writers
Posted on 09 Aug 2017
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder that results in the gradual deterioration of specific brain regions that hinders the person’s ability to think, recall memories, learn, and perform daily tasks.

Currently, AD is diagnosed using the “evaluate and eliminate” approach. More...
With this strategy, patient history, physical exams, laboratory tests, imaging scans, and neurophysiological assessments are examined by doctors as a means to diagnose AD and determine its progression.

Scientists at Ohio State University (Columbus, OH, USA) and their colleagues analyzed 34 cerebrospinal fluid (CSF) samples from 24 patients with AD and from 10 healthy individuals serving as controls. They analyzed 30 serum samples from 22 patients with AD and from eight healthy individuals serving as controls. The processed CSF samples were combined with rabbit-derived primary antibodies anti-Aβ(1–42) antibody) and anti-tau) and goat-derived anti-rabbit secondary antibody in immunofluorescence assays.

A CSF sample of 10 μL was dried on a slide glass surface for atomic force microscopy (AFM) nanomechanics characterization. Hyperspectral microscope imaging was used for particle visualization and analysis and using the system, images of micro-/nanoscale structures and micro-/nanoparticles were captured. Coated with gold and anti-Aβ(1–42) antibody, AFM tips were functionalized to specifically detect the Aβ-embedded proteins inside human serum. Serum or anti-Aβ(1–42) antibody was used to coat the substrates, respectively.

The scientists showed that showed that nanoscale physical properties of protein aggregates from the cerebral spinal fluid and blood of patients are altered during AD pathogenesis and that these properties can be used as a new class of “physical biomarkers”. Using a computational algorithm, developed to integrate these biomarkers and cognitive assessments, they demonstrated an approach to impartially diagnose AD and predict its progression.

Mingjun Zhang, PhD, DSc, a professor of Biomechanical Engineering, and lead investigator of the study said, “With a tool like this you may predict how fast this disease will go, and currently we can't do that, we just know everyone is different. Looking at multiple indicators of the disease all at once increases the reliability of the diagnosis and prognosis.” The study was published on July 28, 2017, in the journal Science Advances.

Related Links:
Ohio State University


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.